Emcure Pharmaceuticals Ltd - Company Profile
Powered by 
All the sales intelligence you need on Emcure Pharmaceuticals Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Emcure Pharmaceuticals Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Emcure Pharmaceuticals Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Emcure Pharmaceuticals Ltd (Emcure) is a global healthcare company. It develops, manufactures, and markets a diverse range of pharmaceutical products across therapeutic areas such as gynecology, cardiology, oncology, blood-related disorders, HIV and others. Emcure develops a wide array of formulations, including biotechnology products. Through its subsidiary, Gennova Biopharmaceuticals Ltd, Emcure advances biologics for life-threatening diseases, focusing on cardiology, nephrology, and oncology. It has launched six biologics globally, including Elaxim, Tenectase, Vintor, Xgrast, Pegex, Emgrast M, and Hamsyl. The company also manufactures active pharmaceutical ingredients (APIs). It has a presence in various countries, including key markets like India, Europe, Canada, Russia, and Brazil. Emcure is headquartered in Pune, Maharashtra, India.
Headquarters
India
Address
Plot No. P-1 And P-2, It-Bt Park, Phase Ii, M.I.D.C., Hinjawadi, Pune, Maharashtra, 411057
Website
www.emcure.com
Telephone
91 20 35070033
No of Employees
11,474
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EMCURE (NSE)
Revenue (2025)
$943.7M
18.6%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
36.8%
(2025 vs 2024)
Market Cap*
$3.6B
Net Profit Margin (2025)
XYZ
15.4%
(2025 vs 2024)
* As of and is in US$
Emcure Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Formulations | Orofer XT |
| Biologics | AquaOat |
| Active Pharmaceutical Ingredients | Pause |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In November, the company entered into a partnership with Novo Nordisk India to launch Poviztra, semaglutide injection 2.4 mg, in India. |
| 2025 | Acquisitions/Mergers/Takeovers | In October, the company acquired the remaining 20.42% stake in Zuventus Healthcare Ltd. |
| 2025 | Contracts/Agreements | In July, the company entered into an agreement with Sanofi India Limited for the promotion of SIL’s oral anti-diabetic (OAD) products in India. |
Competitor Comparison
| Key Parameters | Emcure Pharmaceuticals Ltd | Charles River Laboratories International Inc | Alcami Corp | Endo International Plc | Labcorp Drug Development Inc |
|---|---|---|---|---|---|
| Headquarters | India | United States of America | United States of America | Ireland | United States of America |
| City | Pune | Wilmington | Wilmington | Dublin | Burlington |
| State/Province | Maharashtra | Massachusetts | North Carolina | Dublin | North Carolina |
| No. of Employees | 11,474 | 18,300 | - | 2,931 | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tajuddin Sabir Shaikh | Chief Financial Officer | Senior Management | - | - |
| Sunil Rajanikant Mehta | Director | Executive Board | 2013 | - |
| Anil Chandra Kothiyal | President - India Sales and Markting | Senior Management | - | - |
| Deepak Gondaliya | President - Technical Operations | Senior Management | - | - |
| Sanjay Singh | Chief Executive Officer and Director-Gennova Biopharmaceuticals Ltd | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer